SOUTH SAN FRANCISCO, Calif.,
Aug. 21, 2020 /PRNewswire/
-- Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that
it has granted awards pursuant to the Rigel Pharmaceuticals, Inc.
Inducement Plan, approved by the Compensation Committee of Rigel's
Board of Directors and granted as an inducement material to an
employee's employment with Rigel, in accordance with NASDAQ Listing
Rule 5635(c)(4). Specifically, Rigel granted 250,000 stock
options to David A. Santos, Rigel's
newly appointed EVP and Chief Commercial Officer, vesting over four
years with a one-year cliff. Additionally, Mr. Santos was
granted 250,000 stock options to vest upon achievement of certain
future performance conditions. Each option to purchase has an
exercise price equal to the closing price of Rigel's common stock
on August 19, 2020, the date of
grant.
Rigel is providing this information in accordance with NASDAQ
Listing Rule 5635(c)(4).
About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc., is a biotechnology company
dedicated to discovering, developing and providing novel small
molecule drugs that significantly improve the lives of patients
with immune and hematologic disorders, cancer and rare diseases.
Rigel's pioneering research focuses on signaling pathways that are
critical to disease mechanisms. The company's first FDA approved
product is TAVALISSE® (fostamatinib disodium
hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK)
inhibitor, for the treatment of adult patients with chronic immune
thrombocytopenia who have had an insufficient response to a
previous treatment. The product has been approved by the European
Commission for the treatment of chronic immune thrombocytopenia in
adult patients who are refractory to other treatments and is
marketed in Europe under the name
TAVLESSE® (fostamatinib). Fostamatinib is currently
being studied in an investigator-sponsored trial conducted by
Imperial College London for the treatment of COVID-19
pneumonia1.
Rigel's clinical programs include a Phase 3 study of
fostamatinib in warm autoimmune hemolytic anemia (AIHA); a
completed Phase 1 study of R8351, a proprietary molecule
from its interleukin receptor associated kinase (IRAK) inhibitor
program; and an ongoing Phase 1 study of R5521, a
proprietary molecule from its receptor-interacting protein kinase
(RIP) inhibitor program. In addition, Rigel has product candidates
in clinical development with partners AstraZeneca, BerGenBio ASA,
and Daiichi Sankyo.
Please see www.TAVALISSE.com for the full Prescribing
Information.
1The product for this use or indication is
investigational and has not been proven safe or effective by any
regulatory authority.
IR Contact: David Burke
Phone: 650.624.1232
Email: dburke@rigel.com
View original
content:http://www.prnewswire.com/news-releases/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301116102.html
SOURCE Rigel Pharmaceuticals, Inc.